- $7.04bn
- $6.94bn
- $1.57bn
- 85
- 32
- 60
- 61
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | 18.06 | ||
| PEG Ratio (f) | 0.51 | ||
| EPS Growth (f) | 54.5% | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 1.76 | ||
| Price to Tang. Book | 4.3 | ||
| Price to Free Cashflow | 42.64 | ||
| Price to Sales | 4.49 | ||
| EV to EBITDA | 24.91 | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | 2.84% | ||
| Return on Equity | 4.2% | ||
| Operating Margin | 8.49% | ||
Financial Summary
| Year End 31st Dec | Unit | 2019 | 2020 | 2021 | 2022 | 2023 | 2024E | 2025E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | 785.37 | 789.04 | 958.1 | 1,022.84 | 1,568.48 | 2,464.46 | 2,650.65 | 17.08% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | -2.89 | -32.97 | +55.19 | +18.09 | -20.81 | +77.37 | +22.15 | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Globus Medical, Inc. is a medical device company that develops and commercializes healthcare solutions with a focus on improving the quality of life of patients with musculoskeletal disorders. The Company offers a portfolio of differentiated technologies that are used to treat a variety of musculoskeletal conditions. Musculoskeletal Solutions consist primarily of implantable devices, biologics, accessories, and surgical instruments used in a range of spinal, orthopedic and neurosurgical procedures. Its spine products address the majority of conditions affecting the spine, including degenerative conditions, deformity, tumors, and trauma. It provides solutions that facilitate both open and minimally invasive surgery (MIS) techniques. It includes traditional fusion implants, such as pedicle screws and rod systems. Its orthopedic trauma solutions are designed to treat a variety of orthopedic fracture patterns and patient anatomies in the upper and lower extremities, as well as the hip.
Directors
- David Paul CHM (54)
- David Demski PRE (63)
- Keith Pfeil CFO (42)
- Daniel Scavilla EVP (56)
- Kelly Huller SVP (49)
- David Davidar IND (55)
- Robert Douglas IND (61)
- Daniel Lemaitre IND (67)
- Ann Rhoads IND (56)
- James Tobin IND (76)
- Stephen Zarrilli IND (59)
- Last Annual
- December 31st, 2023
- Last Interim
- December 31st, 2023
- Incorporated
- March 3rd, 2003
- Public Since
- March 8th, 2012
- No. of Shareholders
- 65
- No. of Employees
- 5,000
- Sector
- Healthcare Equipment & Supplies
- Industry
- Healthcare
- Exchange
New York Stock Exchange- Shares in Issue
- 136,335,662
- Address
- 2560 General Armistead Ave, AUDUBON, 19403-5214
- Web
- https://www.globusmedical.com/
- Phone
- +1 6109301800
- Contact
- Brian Kearns
- Auditors
- Deloitte & Touche LLP
Upcoming Events for GMED
Globus Medical Inc Annual Shareholders Meeting
Q2 2024 Globus Medical Inc Earnings Release
Similar to GMED
Abbott Laboratories
New York Stock Exchange
Agilent Technologies
New York Stock Exchange
Agiliti
New York Stock Exchange
Alcon AG
New York Stock Exchange
Artivion
New York Stock Exchange
FAQ
What is the Globus Medical share price?
As of Today at 19:09 UTC, shares in Globus Medical are trading at $51.67. This share price information is delayed by 15 minutes.
How has the Globus Medical share price performed this year?
Shares in Globus Medical last closed at $51.67 and the price had moved by -11.08% over the past 365 days. In terms of relative price strength the Globus Medical share price has underperformed the S&P500 Index by -28.19% over the past year.
What are the analyst and broker recommendations for Globus Medical?
The overall consensus recommendation for Globus Medical is Buy. You can view the full broker recommendation list by unlocking its StockReport.
What is the Globus Medical dividend yield?
Globus Medical does not currently pay a dividend.
Does Globus Medical pay a dividend?
Globus Medical does not currently pay a dividend.
When does Globus Medical next pay dividends?
Globus Medical does not currently pay a dividend.
How do I buy Globus Medical shares?
To buy shares in Globus Medical you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Globus Medical?
As of the previous close price of $51.67, shares in Globus Medical had a market capitalisation of $7.04bn.
Where are Globus Medical shares listed?
Here are the trading details for Globus Medical:
- Country of listing: United States
- Exchange: NYQ
- Ticker Symbol: GMED
What kind of share is Globus Medical?
Based on an overall assessment of its quality, value and momentum Globus Medical is currently classified as a High Flyer. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Globus Medical share price forecast for 2024?
The analyst consensus target price for shares in Globus Medical is $61.46. That is 18.95% above the last closing price of $51.67.
Analysts covering Globus Medical currently have a consensus Earnings Per Share (EPS) forecast of $2.69 for the next financial year.
What is the trend in the Globus Medical share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Globus Medical. Over the past six months, its share price has underperformed the S&P500 Index by -16.96%.
As of the last closing price of $51.67, shares in Globus Medical were trading -2.27% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Globus Medical PE Ratio?
The Globus Medical PE ratio based on its reported earnings over the past 12 months is 18.06. The shares last closed at $51.67.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Globus Medical?
Globus Medical's management team is headed by:
- David Paul - CHM
- David Demski - PRE
- Keith Pfeil - CFO
- Daniel Scavilla - EVP
- Kelly Huller - SVP
- David Davidar - IND
- Robert Douglas - IND
- Daniel Lemaitre - IND
- Ann Rhoads - IND
- James Tobin - IND
- Stephen Zarrilli - IND